3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Blood Specimen Collection
31
Sorafenib
29
Nivolumab
29
Bevacizumab
26
Data Collection
24
Observation
23
palbociclib
22
Sunitinib
22
radium Ra 223 dichloride
20
enzalutamide
18
Rituximab
18
Ipilimumab
16
regorafenib
15
Drug Therapy
15
Trastuzumab
14
Docetaxel
14
ribociclib
12
exemestane
12
atezolizumab
12
Standard of Care
12
darolutamide
11
apalutamide
11
Leuprolide
11
Capecitabine
11
Afatinib
11
Bortezomib
10
Anastrozole
10
trastuzumab deruxtecan
9
pembrolizumab
9
avelumab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Observational
×
Blood Component Removal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled